Umeda Masanori, Okuda Shinya, Izumi Haruka, Nagase Daisuke, Fujimoto Yoshinori, Sugasawa Yasuyuki, Arai Chiaki, Natori Kazuhiko, Katoh Masako, Kuraishi Yasunobu
Division of Hematology and Oncology, Department of Internal Medicine, Toho University School of Medicine, 6-11-1, Omori-nishi, Ota-Ku, Tokyo, 143-8541, Japan.
Ann Hematol. 2006 Jul;85(7):469-73. doi: 10.1007/s00277-006-0095-3. Epub 2006 Mar 10.
We studied the serum phosphorus (P) level of 110 patients with multiple myeloma (MM) (age range 42-83 years, median 62 years) and evaluated the relationship between that and other prognostic factors. Serum P level significantly correlated with the prognostic factors that are relevant to renal dysfunction: serum creatinine (P<0.00000001), serum beta2-microglobulin (P=0.00000088), serum uric acid (P=0.0000014), and corrected serum calcium (cCa P=0.000067). Although it also correlated with the percentage of plasma cells in bone marrow nucleated cells (BMPC%) and the hemoglobin (Hb) and leukocyte counts, the significance was less than for the other four prognostic factors. Serum creatinine, BMPC%, leukocyte count, serum uric acid, bone lesions, beta2-microglobulin, and serum cCa were all significantly higher and Hb significantly was lower in the MM patients with hyperphosphatemia (serum P>3.8 mg/dl). The survival time was significantly shorter in these patients (P=0.000087). Multivariate analysis (Cox's proportional hazards regression model) showed that the serum P level is a significant negative prognostic factor in MM patients.
